Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey. (10th December 2020)

• Record Type: Journal Article
• Authors: Bajema, Kristina L; Dahlgren, F Scott; Lim, Travis W; Bestul, Nicolette; Biggs, Holly M; Tate, Jacqueline E; Owusu, Claudio; Szablewski, Christine M; Drenzek, Cherie; Drobeniuc, Jan; Semenova, Vera; Li, Han; Browning, Peter; Desai, Rita; Epperson, Monica; Jia, Lily T; Thornburg, Natalie J; Edens, Chris; Fry, Alicia M; Hall, Aron J; Schiffer, Jarad; Havers, Fiona P
• Is Part Of: Clinical infectious diseases. Volume 73:Number 9(2021)
• Page Start: e3120
• Page End: e3123
• Publication Date: 2020-12-10
• Subjects: severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) -- seroprevalence -- coronavirus disease 2019 (COVID-19) -- convenience sampling; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1804
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.